Search Results - "Ravikumar, Tadiparthi"

Design of novel amidoxime ketolide core and an efficient synthesis of WCK 4763: for treatment of gram-positive pneumococci by Bhavsar, Satish, Tadiparthi, Ravikumar, Pawar, Shivaji, Kayastha, Abhijeet K., Chavan, Vijay, Yeole, Ravindra, Deshpande, Prasad, Bhagwat, Sachin, Patel, Mahesh

“…Ketolides are the next generation macrolides, which shows broad spectrum of activity against macrolide resistant species, Streptococcus pneumoniae and…”
Get full text

Design and development of efficient synthetic strategies for the chiral synthesis of novel ketolide antibiotic, nafithromycin (WCK 4873) by Bhavsar, Satish, Tadiparthi, Ravikumar, Gupta, Sunil, Pawar, Shivaji, Yeole, Ravindra, Kayastha, Abhijeet K., Deshpande, Prasad, Bhagwat, Sachin, Patel, Mahesh

“…In structure activity relationship-driven novel ketolide drug development program at Wockhardt, the reaction between racemic…”
Get full text

Nafithromycin (MIQNAF®): ultramodern lactone ketolide designed to treat community acquired bacterial pneumonia (CABP) by Bhawsar, Satish, Tadiparthi, Ravikumar, Kayastha, Abhijeet K., Dixit, Prasad, Pavase, Laxmikant, Mishra, Amit, Chavan, Vijay, Birajdar, Satish, Shaikh, Mohammad, Yeole, Ravindra, Bhagwat, Sachin, Patel, Mahesh

“…Community acquired bacterial pneumoniae (CABP) infections is the major cause of mortality and morbidity, especially in elderly patients. India accounts for 23%…”
Get full text

WCK 4873 (INN: Nafithromycin): Structure–activity relationship (SAR) identifying a novel lactone ketolide with activity against Streptococcus pneumoniae (SPN) and Streptococcus pyogenes (SPY) by Bhavsar, Satish, Ravikumar, Tadiparthi, Gupta, Sunil, Pawar, Shivaji, Dabhade, Sanjay, Kayastha, Abhijeet K., Deshpande, Prasad, Yeole, Ravindra, Nandanwar, Manohar, Bhagwat, Sachin, Patel, Mahesh

“…[Display omitted] Ketolides are the fourth generation semisynthetic macrolides derived from erythromycin A, designed to address the limitations of currently…”
Get full text

Process Development and Scale-Up of the Novel β‑Lactamase Inhibitor WCK 6395 by Tamboli, Yasinalli, Kilbile, Jaydeo T., Deshmukh, Vikas, Rane, Vipul, Tadiparthi, Ravikumar, Yeole, Ravindra, Merwade, Arvind Y.

“…The initial process development of the novel β-lactamase inhibitor WCK 6395 is described. All key intermediates were readily isolated by either crystallization…”
Get full text

Strategic Approaches to Overcome Resistance against Gram-Negative Pathogens Using β‑Lactamase Inhibitors and β‑Lactam Enhancers: Activity of Three Novel Diazabicyclooctanes WCK 5153, Zidebactam (WCK 5107), and WCK 4234 by Papp-Wallace, Krisztina M, Nguyen, Nhu Q, Jacobs, Michael R, Bethel, Christopher R, Barnes, Melissa D, Kumar, Vijay, Bajaksouzian, Saralee, Rudin, Susan D, Rather, Philip N, Bhavsar, Satish, Ravikumar, Tadiparthi, Deshpande, Prasad K, Patil, Vijay, Yeole, Ravindra, Bhagwat, Sachin S, Patel, Mahesh V, van den Akker, Focco, Bonomo, Robert A

“…Limited treatment options exist to combat infections caused by multidrug-resistant (MDR) Gram-negative bacteria possessing broad-spectrum β-lactamases. The…”
Get full text